The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Harbour BioMed have entered into an exclusive license agreement with Windward Bio AG for the global development and commercialization of the antibody SKB378/HBM9378, excluding certain Asian regions. This partnership, supported by a significant financing round, is poised to enhance the global reach of SKB378/HBM9378, leveraging combined expertise to maximize its market presence, especially in the treatment of advanced immunological conditions like asthma and COPD.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in China, focusing on the biopharmaceutical industry. The company engages in the development of innovative monoclonal antibodies for various immunological conditions.
YTD Price Performance: -1.59%
Average Trading Volume: 322,223
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$35.81B
For detailed information about 6990 stock, go to TipRanks’ Stock Analysis page.